Russell Investments Group
NPCE icon

Russell Investments Group’s Neuropace NPCE Stock Holding History

Russell Investments Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Buy
179,021
+105,329
+143% +$1.58M ﹤0.01% 1791
2025
Q4 		$1.14M Buy
73,692
+6,484
+10% +$86.7K ﹤0.01% 2157
2025
Q3 		$693K Sell
67,208
-4,255
-6% -$40.1K ﹤0.01% 2339
2025
Q2 		$796K Buy
71,463
+26,547
+59% +$332K ﹤0.01% 2165
2025
Q1 		$552K Buy
+44,916
New +$562K ﹤0.01% 2267

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Russell Investments Group's NPCE Position: Q1 2026 in Review

Russell Investments Group increased its Neuropace (NPCE) stake by 143% in Q1 2026, buying an estimated $1.58M and bringing the position to 179,021 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

Russell Investments Group first reported a position in NPCE in Q1 2025 and has held it in 5 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Russell Investments Group held 179,021 shares of Neuropace worth $2.35M as of Q1 2026.
  • Russell Investments Group bought 105,329 Neuropace shares in Q1 2026, an estimated $1.58M.
  • Neuropace made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #1791 holding.
  • Russell Investments Group first reported a position in Neuropace in Q1 2025 and has held it in 5 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.